Paul Aisen

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease
    Paul S Aisen
    University of California, San Diego, California 92093, USA
    Cold Spring Harb Perspect Med 2:a006395. 2012
  2. pmc Clinical trial methodologies for disease-modifying therapeutic approaches
    Paul S Aisen
    Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, USA
    Neurobiol Aging 32:S64-6. 2011
  3. pmc Recent developments in Alzheimer's disease therapeutics
    Michael S Rafii
    Department of Neurosciences, University of California San Diego, Gilman Drive M C 0949, La Jolla, CA 92093, USA
    BMC Med 7:7. 2009
  4. pmc Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
    Randall J Bateman
    Department of Neurology, Washington University School of Medicine, 660 S, Euclid, Campus Box 8111, St Louis, MO 63110, USA
    Alzheimers Res Ther 3:1. 2011
  5. pmc High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial
    Paul S Aisen
    Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, M C 0949, La Jolla, CA 92093, USA
    JAMA 300:1774-83. 2008
  6. pmc Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans
    Paul S Aisen
    Department of Neurosciences, University of California San Diego, CA, USA
    Alzheimers Dement 6:239-46. 2010
  7. doi Longitudinal change of biomarkers in cognitive decline
    Raymond Y Lo
    Division of Epidemiology, University of California, Berkeley, 94720 3190, USA
    Arch Neurol 68:1257-66. 2011
  8. pmc Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures
    Douglas R Galasko
    Department of Neurosciences, University of California, San Diego, 92093, USA
    Arch Neurol 69:836-41. 2012
  9. pmc Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis
    Linda K McEvoy
    Department of Radiology, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA
    Radiology 259:834-43. 2011
  10. pmc Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment
    Danielle C Whitehair
    Department of Neurosciences, University of California, San Diego, CA, USA
    Alzheimers Dement 6:412-9. 2010

Detail Information

Publications29

  1. pmc Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease
    Paul S Aisen
    University of California, San Diego, California 92093, USA
    Cold Spring Harb Perspect Med 2:a006395. 2012
    ..We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau...
  2. pmc Clinical trial methodologies for disease-modifying therapeutic approaches
    Paul S Aisen
    Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, USA
    Neurobiol Aging 32:S64-6. 2011
    ..Data suggest that neuroimaging biomarkers will be useful as endpoints for trials in very early, even asymptomatic disease, though further work is necessary to establish validity for regulatory purposes...
  3. pmc Recent developments in Alzheimer's disease therapeutics
    Michael S Rafii
    Department of Neurosciences, University of California San Diego, Gilman Drive M C 0949, La Jolla, CA 92093, USA
    BMC Med 7:7. 2009
    ..In this review, we briefly discuss the current status of Alzheimer's disease therapies under study, as well the scientific context in which they have been developed...
  4. pmc Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
    Randall J Bateman
    Department of Neurology, Washington University School of Medicine, 660 S, Euclid, Campus Box 8111, St Louis, MO 63110, USA
    Alzheimers Res Ther 3:1. 2011
    ..Clinical trials in autosomal-dominant Alzheimer's disease may test the amyloid hypothesis, determine the timing of treatment, and lead the way to Alzheimer's disease prevention...
  5. pmc High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial
    Paul S Aisen
    Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, M C 0949, La Jolla, CA 92093, USA
    JAMA 300:1774-83. 2008
    ..Prior studies of B vitamins to reduce homocysteine in AD have not had sufficient size or duration to assess their effect on cognitive decline...
  6. pmc Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans
    Paul S Aisen
    Department of Neurosciences, University of California San Diego, CA, USA
    Alzheimers Dement 6:239-46. 2010
    ..The resulting data would provide valuable data on the earliest stages of AD, and support the development of interventions in these critically important populations...
  7. doi Longitudinal change of biomarkers in cognitive decline
    Raymond Y Lo
    Division of Epidemiology, University of California, Berkeley, 94720 3190, USA
    Arch Neurol 68:1257-66. 2011
    ....
  8. pmc Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures
    Douglas R Galasko
    Department of Neurosciences, University of California, San Diego, 92093, USA
    Arch Neurol 69:836-41. 2012
    ..To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers...
  9. pmc Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis
    Linda K McEvoy
    Department of Radiology, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA
    Radiology 259:834-43. 2011
    ..To assess whether single-time-point and longitudinal volumetric magnetic resonance (MR) imaging measures provide predictive prognostic information in patients with amnestic mild cognitive impairment (MCI)...
  10. pmc Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment
    Danielle C Whitehair
    Department of Neurosciences, University of California, San Diego, CA, USA
    Alzheimers Dement 6:412-9. 2010
    ..We examine the prospective association of APOE varepsilon4 allele status on measures of cognitive and functional decline in subjects with amnestic MCI (aMCI)...
  11. pmc Effect of study partner on the conduct of Alzheimer disease clinical trials
    Joshua D Grill
    Mary Easton Center for Alzheimer s Disease Research, University of California, Los Angeles, USA
    Neurology 80:282-8. 2013
    ..Alzheimer disease (AD) dementia clinical trials require 2 participants: a patient and a study partner. We assessed the prevalence of study partner types and how these types associate with patient-related outcome measures...
  12. pmc CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects
    Michael Ewers
    Department of Radiology, University of California, San Francisco, 94143, USA
    Cereb Cortex 22:1993-2004. 2012
    ....
  13. pmc Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials
    Lon S Schneider
    Department of Psychiatry, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Alzheimers Dement 6:367-77. 2010
    ....
  14. pmc 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
    Hum Brain Mapp 31:786-97. 2010
    ..Greater CA1 and subicular atrophy can be demonstrated early and is predictive of future conversion to AD, whereas CA2-3 involvement becomes more evident as the disease progresses...
  15. pmc Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects
    E C Mormino
    Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA 94720, USA
    Brain 132:1310-23. 2009
    ..This pattern suggests that declining EM in older individuals may be caused by Abeta-induced hippocampus atrophy...
  16. pmc Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease
    Linda K McEvoy
    Department of Radiology, University of California, San Diego, La Jolla, CA 92093 0841, USA
    Alzheimer Dis Assoc Disord 24:269-77. 2010
    ..Failure to take into account normal age-related changes risks under-powering trials designed to test disease-modifying properties of potential treatments...
  17. pmc Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease
    Adam S Fleisher
    University of California, San Diego, La Jolla, CA 92037, USA
    Arch Neurol 65:1031-8. 2008
    ..To evaluate the safety, tolerability, and amyloid beta (Abeta) response to the gamma-secretase inhibitor LY450139 in Alzheimer disease...
  18. pmc MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population
    Rema Raman
    Department of Neurosciences, University of California San Diego, La Jolla, 92093 0717, USA
    Alzheimer Dis Assoc Disord 23:333-6. 2009
    ..To determine if a self-selected group of participants who enroll in an imaging substudy of Alzheimer disease (AD) clinical trials is representative of the overall study sample...
  19. ncbi Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials
    Michael Grundman
    Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California San Diego, 8950 Villa La Jolla Drive, Suite 227, La Jolla, CA 92037, USA
    Arch Neurol 61:59-66. 2004
    ..The Memory Impairment Study (MIS) is a multicenter clinical trial in patients with MCI designed to evaluate whether vitamin E or donepezil is effective at delaying the time to a clinical diagnosis of AD...
  20. pmc The Alzheimer's disease neuroimaging initiative: progress report and future plans
    Michael W Weiner
    Center for Imaging of Neurodegenerative Diseases, San Francisco VA Medical Center, San Francisco, CA, USA
    Alzheimers Dement 6:202-11.e7. 2010
    ..All data are available at UCLA/LONI/ADNI, without embargo. ADNI-like projects started in Australia, Europe, Japan, and Korea. ADNI provides significant new information concerning the progression of AD...
  21. pmc NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia
    Steven D Edland
    Department of Neurosciences, University of California San Diego, La Jolla, CA, USA
    Alzheimer Dis Assoc Disord 24:159-64. 2010
    ..Targeted retention efforts and utilization of academic sites could substantively improve the statistical power and validity of future clinical trials of cognitively impaired elderly...
  22. doi Dependence as a unifying construct in defining Alzheimer's disease severity
    Trent McLaughlin
    Janssen Alzheimer Immunotherapy Research and Development, South San Francisco, CA, USA
    Alzheimers Dement 6:482-93. 2010
    ..This article presents the concept of dependence on others for care needs as a potential method for translating the effect of changes in cognition, function, and behavior into a more holistic, transparent description of AD progression...
  23. pmc Subregional neuroanatomical change as a biomarker for Alzheimer's disease
    Dominic Holland
    Department of Neurosciences, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Proc Natl Acad Sci U S A 106:20954-9. 2009
    ..The findings indicate that regional temporal lobe cortical changes would have great utility as outcome measures in clinical trials and may also have utility in clinical practice for aiding early diagnosis of neurodegenerative disease...
  24. pmc Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes
    Gloria C Chiang
    Department of Radiology, University of California, San Francisco, 505 Parnassus Ave, Room M391, San Francisco, CA, 94143, USA
    Radiology 259:844-51. 2011
    ..To determine whether automated temporoparietal brain volumes can be used to accurately predict future memory decline among a multicenter cohort of cognitively healthy elderly individuals...
  25. pmc Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative
    Owen Carmichael
    Department of Neurology, School of Medicine, University of California, Davis, CA, USA
    Arch Neurol 67:1370-8. 2010
    ....
  26. pmc Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans
    Trygve E Bakken
    Medical Scientist Training Program, University of California at San Diego, La Jolla, CA 92093, USA
    Proc Natl Acad Sci U S A 109:3985-90. 2012
    ..We suggest that identifying genes that contribute to normal cortical architecture provides a first step to understanding genetic mechanisms that underlie visual perception...
  27. pmc Voxelwise genome-wide association study (vGWAS)
    Jason L Stein
    Laboratory of Neuro Imaging, Department of Neurology, University of California, Los Angeles School of Medicine, Neuroscience Research Building 225E, 635 Charles Young Drive, Los Angeles, CA 90095 1769, USA
    Neuroimage 53:1160-74. 2010
    ..These genes have high relevance to brain structure. This is the first voxelwise genome wide association study to our knowledge, and offers a novel method to discover genetic influences on brain structure...
  28. doi Applications of neuroimaging to disease-modification trials in Alzheimer's disease
    Adam S Fleisher
    Department of Neurosciences, University of California, San Diego, USA
    Behav Neurol 21:129-36. 2009
    ..This review discusses recently presented data from the ADNI dataset, and the importance of imaging in the future of drug development in AD...
  29. doi Leon Thal and the therapeutic age of Alzheimer's disease
    Paul S Aisen
    University of California San Diego, San Diego, CA, USA
    Alzheimers Dement 4:S4-6. 2008

Research Grants5

  1. Pilot Study of Huperzine A in Alzheimer's Disease
    Paul Aisen; Fiscal Year: 2003
    ....
  2. A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer's Disease
    Paul Aisen; Fiscal Year: 2009
    ..Alzheimer's disease is among the most important health problems worldwide, with steadily rising prevalence as populations age. Effective disease-modifying treatment is sorely needed. ..
  3. A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer's Disease
    Paul S Aisen; Fiscal Year: 2010
    ..Alzheimer's disease is among the most important health problems worldwide, with steadily rising prevalence as populations age. Effective disease-modifying treatment is sorely needed. ..